[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","Programmed Cell Death 1 Ligand 1",27,[8,16,22,28,35,41,47,53,59,65,71,77,83,89,95,102,108,114,120,126,131,137,142,148,154,161,167],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:26.669629Z","2026-06-17T19:21:16.689089Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07227298","Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:29.138008Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT04796012","VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed\u002FRefractory Solid Tumors",[12],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.853446Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06234397","Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors",[32],"Phase 1","2026-08-26T02:17:12.307088Z","2026-05-05T02:43:27.845053Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07532902","A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",[32],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.689344Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05784688","Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.298307Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05458219","A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors",[32],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:29.294686Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05067283","A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)",[32],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:27.569866Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:35:31.728570Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT03526835","A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:17:16.126291Z","2026-07-30T01:46:14.461456Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:19:03.581490Z","2026-07-24T01:27:14.928476Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT05719558","A Study of ASP1002 in Adults for Treatment of Solid Tumors",[32],"2026-08-26T02:16:05.813655Z","2026-07-24T01:27:14.892649Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT06021626","A Study of CRD3874-SI in People With Solid Tumors",[32],"2026-08-26T02:16:32.589113Z","2026-07-05T05:32:16.744495Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT07287995","A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors",[12],"2026-08-26T02:19:11.399072Z","2026-07-05T05:32:16.680665Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":100,"content_modified":101},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[99],"Phase 2","2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07115043","A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.700642Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05533697","Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:29.371442Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07205718","A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:29.041246Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":100,"content_modified":130},"NCT05267626","Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",[12],"2026-05-05T02:43:28.878293Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT07436728","A Study of TAK-505 in Adults With Solid Tumors",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:28.538954Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":87,"content_modified":141},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[32],"2026-05-05T02:43:27.807952Z",{"nct_id":143,"title":144,"phases":145,"status":13,"updated_at":146,"content_modified":147},"NCT05176483","Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors",[32],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.678164Z",{"nct_id":149,"title":150,"phases":151,"status":13,"updated_at":152,"content_modified":153},"NCT07646847","A Study of a Side Effects and Resource Navigation Program for People With Cancer",[],"2026-08-26T02:18:45.196599Z","2026-07-30T01:46:14.435535Z",{"nct_id":155,"title":156,"phases":157,"status":158,"updated_at":159,"content_modified":160},"NCT04626635","A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:12:30.468079Z","2026-05-05T02:43:27.635088Z",{"nct_id":162,"title":163,"phases":164,"status":158,"updated_at":165,"content_modified":166},"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",[32],"2026-08-03T03:38:39.261584Z","2026-05-05T02:43:29.038880Z",{"nct_id":168,"title":169,"phases":170,"status":158,"updated_at":171,"content_modified":172},"NCT04291105","Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",[99],"2026-08-03T02:31:37.197247Z","2026-05-05T02:43:28.820519Z"]